Background: Hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP) has shown to be overexpressed in several human cancers. The purpose of this study was to explore the expression of HPIP in endometrial cancer (EC) and its associated effects on disease.
| INTRODUC TI ON
Endometrial cancer (EC) is one of the most common cancers in women worldwide. 1 According to reports in the literature, the incidence of endometrial cancer in developed countries is higher than in developing countries. However, more and more women in China have been diagnosed with endometrial cancer in recent years. 2, 3 Despite advances in the standard treatment for endometrial cancer, the prognosis in most patients with advanced endometrial cancer remains unsatisfactory. Therefore, it is imperative to further explore the occurrence and development of endometrial cancer progression and to identify therapeutic targets.
Hematopoietic pre-B-cell leukemia transcription factor-interacting protein (HPIP) was originally identified by a yeast two-hybrid screening of a hematopoietic cDNA library. According to the currently reported studies, HPIP exhibited an excessive expression status in numerous cancer tissues, while HPIP expression is involved in various aspects of cancer progression and predicts poor prognosis in cancer patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, by reviewing the literature, we have not found a report on the expression of HPIP in endometrial cancer.
Therefore, our research aimed to explore the expression status of HPIP in endometrial cancer and its relationship with clinicopathological features. At the same time, further evidence was provided for the possibility of HPIP as a potential target for the treatment of endometrial cancer.
| MATERIAL S AND ME THODS

| Patient population
This study has been obtained authorization from the Ethical Committee of the Harbin Medical University Cancer Hospital.
Patients of this study have signed written informed consent. In total, 113 endometrial cancer tissues were obtained from the Harbin Medical University Cancer Hospital. All patients received no treatment before surgery, and the cancer tissue samples were from patients who underwent gynecological surgery between August 2011 and September 2012. All patients underwent hysterectomy, bilateral salpingo-oophorectomy, pelvic and/or para-aortic lymphadenectomy, partial oophorectomy, and peritoneal lavage for cytology.
The follow-up ranged from 4 to 74 months, with a median followup of 62 months. All clinical information to be studied is summarized and listed in Table 1 .
| Western blot analysis
Nine samples were frozen in liquid nitrogen. The lysate was mixed proportionally with a protease inhibitor and used to cleave the extracted protein. The BCA method was then used to determine the protein concentration in the sample solution. The next step is electrophoresis separation, membrane transfer, and closure.
After that, the primary antibody (anti-HPIP, 1:300, Abcam, LLC) hybridization and the secondary antibody (anti-β-actin, Santa Cruz Biotechnology) hybridization were carried out, and the membrane was removed for exposure identification. This experiment is repeated three times.
| Immunohistochemistry and evaluation
Detection of HPIP expression by immunohistochemistry. Paraffin specimens were sectioned for immunohistochemistry experiments. Then, dewax, rehydrate, and warm the bath. The antigen was repaired by heating with an autoclave and washed with PBS.
The washed sections were incubated with an anti-HPIP antibody (Abcam, catalogue number [ab176591]) at a dilution of 1:200 in a humid box and stored at 4°C overnight. The secondary antibody is then washed and added to detect bound antibodies. Sections were counterstained with hematoxylin, dehydrated, clarified, and sealed. The positive control for this experiment was a confirmed ovarian cancer wax block, while the negative control used rabbit serum instead of primary antibody staining.
TA B L E 1 Association analyses between the expression levels of HPIP and the clinicopathological characteristics of endometrial carcinoma
The proportion of positive tumor cells was used as the criteria for staining score: 0 (positive tumor cells accounted for less than 5%); 1 (positive tumor cells accounted for 5-25%); 2 (positive tumor cells accounted for 25-75% ); 3 (positive tumor cells accounted for more than 75%). Microscopic staining intensity grading: 0 (no), 1 (weak), 2 (moderate), and 3 (strong). The proportional score is multiplied by the score of the staining grade to obtain the final score. The final score is expressed as low expression (0-2) and high expression (≥3).
All immunohistochemical stains were scored by a professional pathologist who did not know the source of the sample.
| Real-time PCR
The 
| Statistical analysis
| RE SULTS
| HPIP expression in patients with endometrial cancer
A total of 113 endometrial cancers samples were studied in our research for immunohistochemistry analysis. The clinicopathological features of the patients participating in the study are summarized in showed that the expression of HPIP was excessive at protein level in endometrial cancer samples (P < 0.001; Figure 1 ). Real-time PCR results showed that the expression of HPIP at mRNA level in endometrial cancer tissues is much higher than that in normal endometrial tissues (P < 0.05, Figure 2 ).
| HPIP expression is associated with clinicopathological feature in endometrial cancer
To further examine the expression pattern of HPIP in patients with endometrial carcinoma, HPIP expression was detected using Excessive expression of HPIP was clearly associated with high FIGO stage (P < 0.001), deep myometrial invasion (P < 0.001), high histological grade (P < 0.001), and lymph node metastasis (P = 0.033; Table 1 ).
| Association between HPIP expression and prognosis of patients with endometrial cancer
According to HPIP expression, patients could be classified into two patient subgroups: patient group with high expression level of Results of Kaplan-Meier analysis suggested that there was significant difference in overall survival between the two groups of patients stratified by HPIP expression level (log-rank P = 0.002; Figure 4A ). HPIP-overexpressed endometrial cancer patients had shorter median survival time (log-rank P = 0.002; Table 2 ). We further evaluated the capability of the HPIP expression in predicting disease-free survival. In consistent with the findings described above, the two groups of patients stratified by HPIP expression level showed significantly different disease-free survival (log-rank P = 0.002; Figure 4B ). The disease-free survival of the HPIP overexpression group was clearly shorter (log-rank P = 0.002; Table 2 ).
| Independence of HPIP expression from other clinicopathological factors
To assess whether prognosis prediction ability of HPIP expression is independent of other clinicopathological features of patients with endometrial carcinoma, we performed multivariate Cox regression analysis. As shown in Table 3 , the results demonstrated that HPIP expression (HR = 12.614, CI = 1.636-97.278, P = 0.015) was obviously related to overall survival, while HPIP expression (HR = 12.008, CI = 1.561-92.375, P = 0.017) was markedly correlated with diseasefree survival of the endometrial carcinoma. Taken together, these results thus indicated that the predictive value of HPIP expression as a molecular biomarker is independent of other clinicopathological factors (Table 3 ).
| D ISCUSS I ON
In this study, we investigated whether HPIP is highly expressed in endometrial cancer tissues and its association with clinicopathological features. Furthermore, this study also explored the prog- endometrial cancer and it could be used to index the prognosis and metastasis of endometrial cancer.
As shown in Figures 1 and 2 , the consequence of real-time PCR (mRNA levels) and Western blot (protein level) certified that excessive HPIP expression was found in EC samples nevertheless not found in normal samples. In this study, we performed data analysis on the results of immunohistochemistry of 113 endometrial cancer samples. Data analysis showed that overexpressed HPIP was highly correlated with clinicopathological features of endometrial cancer, including FIGO stage, myometrial invasion, histological grade, and lymph node metastasis. All of the above studies indicated that HPIP is involved in and plays a non-negligible element in promoting cancer progression. We found that patients with HPIP high expression had worse disease-free survival and overall survival through Kaplan-Meier analysis and log-rank analysis. As shown in Table 3 , Regarding the study of HPIP in endometrial cancer tissues, our findings are in accordance with findings from various cancer tissues above. All of these findings exposed that HPIP takes part in tumorigenesis and progression. It further implied that HPIP can be a valuable biomarker for predicting cancer progression and prognosis.
Our research has verified that the excessive expression of HPIP In brief, our results indicated that HPIP is excessively expressed in endometrial cancer and that excessive expression of HPIP may be closely related to cancer progression and prognosis. This study provided strong support and evidence for HPIP as a new biomarker and the potential therapeutic target for endometrial cancer. But these findings require more extensive experiments to verify.
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